PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS
Delisted
PHAS was delisted on the 2nd of November, 2022.
61 hedge funds and large institutions have $110M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
5% more funds holding
Funds holding: 58 → 61 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Holders
61
Holding in Top 10
1
Calls
$227K
Puts
$206K
Top Buyers
| 1 | +$14.8M | |
| 2 | +$11.1M | |
| 3 | +$9.86M | |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$7.49M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.8M |
Top Sellers
| 1 | -$371K | |
| 2 | -$280K | |
| 3 | -$187K | |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$173K |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$114K |